Compositions and methods for tunable regulation of transcription
AssigneeObsidian Therapeutics, Inc.
InventorsVipin Suri, Mara Christine Inniss, Samantha Fleury
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods related to transcription factor systems. Such systems provide for modular and tunable protein expression driven by regulated transcriptional activity.
Claims44
(canceled)
A modified cell comprising a first polynucleotide, said first polynucleotide comprising a first nucleic acid sequence that encodes a transcription factor activation domain;
- a second nucleic acid sequence that encodes a transcription factor DNA binding domain that binds to a specific polynucleotide binding site;
- and a third nucleic acid sequence that encodes a drug responsive domain (DRD);
- wherein the transcription factor activation domain, the transcription factor DNA binding domain, or the combination of the transcription factor activation domain and the transcription factor DNA binding domain is operably linked to the DRD;
- wherein the transcription factor activation domain and the transcription factor DNA binding domain interact to form a transcription factor that is able to activate transcription of a fourth nucleic acid sequence upon binding to the specific polynucleotide binding site;
- and
- wherein the fourth nucleic acid sequence encodes a protein of interest and is operably linked to the specific polynucleotide binding site.
4-6. (canceled)
(canceled)
A modified cell comprising a polynucleotide comprising a first nucleic acid sequence encoding a drug responsive domain (DRD) and a second nucleic acid sequence encoding a transcription factor, wherein the transcription factor is operably linked to the DRD;
- and
- wherein the transcription factor is able to bind to a specific polynucleotide binding site and activate transcription of a third nucleic acid sequence encoding a protein of interest, wherein the third nucleic acid sequence is operably linked to the specific polynucleotide binding site.
12-14. (canceled)
17-21. (canceled)
23-28. (canceled)
A nucleic acid molecule comprising:
- a. a first nucleic acid sequence encoding a transcription factor able to bind to a specific polynucleotide binding site and activate transcription;
- and
- b. a second nucleic acid sequence encoding a drug responsive domain (DRD);
- wherein the transcription factor is operably linked to the DRD.
33-37. (canceled)
39-50. (canceled)
A method of producing a modified cell, said method comprising introducing into a cell a nucleic acid molecule comprising:
- a. a first nucleic acid sequence that encodes a transcription factor DNA binding domain that binds to a specific polynucleotide binding site;
- and
- b. a second nucleic acid sequence that encodes a drug responsive domain (DRD).
(canceled)
58-60. (canceled)
(canceled)
66-68. (canceled)
70-73. (canceled)
75-78. (canceled)
Dependencies are inferred from the claim text.